Gross Profit Margin (Quarterly) Chart

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 2014. Start Trial.
Date Value
June 30, 2026 85.08%
March 31, 2026 87.68%
December 31, 2025 87.97%
September 30, 2025 87.80%
June 30, 2025 85.56%
March 31, 2025 88.20%
December 31, 2024 92.80%
September 30, 2024 89.88%
June 30, 2024 90.82%
March 31, 2024 91.02%
December 31, 2023 90.64%
September 30, 2023 90.87%
June 30, 2023 91.41%
March 31, 2023 90.92%
December 31, 2022 92.80%
September 30, 2022 91.03%
June 30, 2022 90.58%
March 31, 2022 90.14%
December 31, 2021 91.01%
September 30, 2021 89.22%
June 30, 2021 90.65%
March 31, 2021 87.85%
December 31, 2020 90.75%
September 30, 2020 81.02%
June 30, 2020 46.40%
Date Value
March 31, 2020 68.61%
December 31, 2019 47.87%
September 30, 2019 2.77%
June 30, 2019 -98.92%
March 31, 2019 -83.74%
December 31, 2018 -38.69%
September 30, 2018 -38.15%
June 30, 2018 -10.96%
March 31, 2018 -89.71%
December 31, 2017 -31.62%
September 30, 2017 -16.06%
June 30, 2017 -4.57%
March 31, 2017 20.84%
December 31, 2016 50.39%
September 30, 2016 53.88%
June 30, 2016 29.25%
March 31, 2016 48.54%
December 31, 2015 33.03%
September 30, 2015 48.65%
June 30, 2015 41.83%
March 31, 2015 46.24%
December 31, 2014 61.58%
September 30, 2014 77.62%
June 30, 2014 -76.29%
March 31, 2014 -277.8%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
EyePoint, Inc. -36.09%
ANI Pharmaceuticals, Inc. 54.97%
Theravance Biopharma, Inc. 93.04%
Corcept Therapeutics, Inc. 98.41%
Veru, Inc. --

Gross Profit Margin (Quarterly) Related Metrics